Halozyme Therapeutics reported U$25.817 million in Net Income for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Acadia Pharmaceuticals U$ -43M 46M
Agios Pharmaceuticals U$ -91M 50M
Alnylam Pharmaceuticals U$ -180M 3M
Amarin U$ -6.788M 11.203M
Amgen U$ 1803M 22M
Baxter International U$ 246M 86M
Cytokinetics U$ -41M 1M
Eli Lilly And U$ 1412M 44.5M
Esperion Therapeutics 12461100 20286000
Halozyme Therapeutics U$ 25.817M 31.92M
Immunogen U$ -24.298M 4.79M
Intercept Pharmaceuticals U$ -63.281M 29.702M
Intrexon U$ -44M 12M
JAZZ PHA U$ 148.234M 33.433M
Mannkind U$ -11M 1M
Minerva Neurosciences U$ 29M 42M
Pfizer U$ 3426M 25M
United Therapeutics U$ 107.1M 30.6M
Vanda Pharmaceuticals U$ 8.714M 8.228M